Millennium Management LLC Buys New Stake in USANA Health Sciences, Inc. (NYSE:USNA)

Millennium Management LLC acquired a new stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 17,637 shares of the company's stock, valued at approximately $633,000. Millennium Management LLC owned 0.09% of USANA Health Sciences at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Pzena Investment Management LLC grew its position in shares of USANA Health Sciences by 3.6% during the 4th quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock valued at $39,015,000 after acquiring an additional 37,466 shares during the period. Principal Financial Group Inc. grew its position in shares of USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after acquiring an additional 1,480 shares during the period. Rhumbline Advisers grew its position in shares of USANA Health Sciences by 39.8% during the 4th quarter. Rhumbline Advisers now owns 49,390 shares of the company's stock valued at $1,773,000 after acquiring an additional 14,068 shares during the period. Dimensional Fund Advisors LP grew its position in shares of USANA Health Sciences by 7.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company's stock valued at $27,751,000 after acquiring an additional 55,059 shares during the period. Finally, Norges Bank bought a new stake in shares of USANA Health Sciences during the 4th quarter valued at $953,000. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Stock Down 3.3%

USNA stock traded down $1.02 during mid-day trading on Wednesday, hitting $29.84. The company had a trading volume of 112,465 shares, compared to its average volume of 135,342. The company has a market capitalization of $555.75 million, a price-to-earnings ratio of 10.54, a P/E/G ratio of 0.93 and a beta of 0.63. USANA Health Sciences, Inc. has a 12-month low of $23.10 and a 12-month high of $48.85. The company has a 50-day moving average price of $27.83 and a 200 day moving average price of $31.27.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.03. The firm had revenue of $249.54 million for the quarter, compared to analysts' expectations of $243.08 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same period in the prior year, the company earned $0.86 EPS. As a group, analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Insider Activity

In other USANA Health Sciences news, COO Walter Noot sold 6,291 shares of the company's stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $30.29, for a total value of $190,554.39. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO G Doug Iiekking sold 4,548 shares of the company's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,013 shares of company stock worth $360,149. 0.63% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on USNA. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th. Wall Street Zen upgraded shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Finally, Sidoti cut shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.